Managed care pharmacy, socioeconomic assessments and drug adoption decisions

Social Science and Medicine

Volumn 45, Issue 4, 1997, Pages 511-521

  Lyles, Alan ^a   Luce, Bryan R ^b   Rentz, Anne M ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Disease management; Formulary; Managed care pharmacy; Pharmacy and Therapeutics Committee; Socioeconomic assessment; Technology assessment

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE MANAGEMENT; DRUG CHOICE; MANAGED CARE; PHARMACY; PUBLICATION; SOCIOECONOMICS; UNITED STATES;

COST CONTROL; DRUG APPROVAL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FORECASTING; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; PHARMACY AND THERAPEUTICS COMMITTEE; PRESCRIPTION FEES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0030742841     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(96)00392-9     Document Type: Article

References (35)

1. Anders, G. (May 17, 1995) Drug makers help manage patient care. Wall Street Journal.
2. Armstrong, E. P. and Langley, P. C. (1996) Disease management programs. American Journal of Health-System Pharmacy 53, 53-58.
3. ASHP (1996) Top eight pharmacy management issues. ASHP Newsletter 29, 8.
4. Blissenbach. H. F. (1993) Pharmaceutical services in managed care. In The Managed Care Handbook, 2nd ed, ed. P. R. Kongstvedt, pp. 142-160. Aspen, Gaithersburg, MD.
5. Cano, S. B. (1996) Formularies in integrated health systems: Fallon Healthcare System. American Journal of Health-System Pharmacy 53, 270-273.
6. GHAA (1995) 1995 National Directory of HMOs. Group Health Association of America, Washington, DC.
7. Hatoum, H. T. and Freeman, R. A. (1994) The use of pharmacoeconomic data in formulary selection. Topics in Hospital Pharmacy Management 13, 47-53.
8. Horn, S. D., Sharkey, P. D., Tracy, D. M., Horn, C. E., James, B. and Goodwin. F. (1996) Intended and unintended consequences of HMO cost-containment strategies: results from the Managed Care Outcomes project. American Journal of Managed Care 2, 253-264.
9. Ito, S. M. and Blackburn, S. (eds) (1995) A Pharmacist's Guide to Principles and Practices of Managed Care Pharmacy. Foundation for Managed Care Pharmacy, Alexandria, VA.
10. Johnson, J. A. and Bootman, J. L. (1994) Pharmacoeconomic analysis in formulary decisions: an international perspective. American Journal of Hospital Pharmacy 51, 2593-2598.
11. Jolicoeur, L. M., Jones-Grizzle, A. J. and Boyer, J. G. (1992) Guidelines for performing a pharmacoeconomic analysis. American Journal Hospital Pharmacy 42, 1741-1747.
12. Kozma, C. M., Reeder, C. E. and Schulz, R. M. (1993) Economic, clinical and humanistic outcomes: a planning model for pharmacoeconomic research. Clinical Therapeutics 15, 1121-1132.
13. Landis, N. T. (1994) Initial triservice formulary ready for use. American Journal of Health-System Pharmacy 51, 588-591.
14. Langley, P. C. (1993) The role of pharmacoeconomic guidelines for formulary approval: the Australian experience. Clinical Therapeutics 15, 1154-1176.
15. Luce, B. R. and Brown, R. E. (1995) The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. International Journal of Technology Assessment in Health Care 11, 79-92.
16. Luce, B. R., Lyles, C. A. and Rentz, A. M. (1996) The view from managed care pharmacy. Health Affairs 15, 168-176.
17. Lyon, R. A. (1990) Formulary-control procedures in a staff-model health maintenance organization. American Journal of Hospital Pharmacy 47, 340-342.
18. Marion Merrell Dow (1994) Managed Care Digest: HMO Edition. MMD, Kansas City, MO.
19. McFarland, B. H. (1994) Cost-effectiveness considerations for managed care systems: treating depression in primary care. American Journal of Medicine 97(6A), 47-58.
20. McGhan, W. F. and Lewis, N. J.W. (1992) Guidelines for pharmacoeconomic studies. Clinical Therapeutics 14, 486-494.
21. National Center for Health Statistics (1994) Health, United States, 1993. Public Health Service, Hyattsville, MD.
22. National Center for Health Statistics (1995) Health, United States, 1994. Public Health Service, Hyattsville, MD.
23. Navarro R. P. (ed.) (1995) CibaGeneva Pharmacy Benefit Report: Trends and Forecasts. Ciga-Geigy Corporation, Summit, NJ.
24. Office of Technology Assessment, OTA-BP-H-159 (1995) Coverage of laser technology by health insurers. Steiner C., Powe N. and Anderson G. (contractors), Washington, DC.
25. Penna, P. M. (1996) Pharmacy factors that influence the success of integrated health care systems. American Journal of Health-System Pharmacy 53(1), S7-S10.
26. Reeder, C. E. (1996) Overview of pharmacoeconomic and pharmaceutical outcomes evaluation. American Journal of Health-System Pharmacy 52(4), S5-S8.
27. Rizos, A. L., Levy, E., Furnier, J. and Crowley, K. (1996) Formularies in integrated health systems: Sharp HealthCare. American Journal of Health-System Pharmacy 53, 274-278.
28. Sacristan, J. A., Soto, J. and Galende, I. (1993) Evaluation of pharmacoeconomic studies: utilization of a checklist. Annals of Pharmacotherapy 27, 1126-1133.
29. Sanchez, L. A. (1995) Evaluating the quality of published pharmaeconomic evaluations. Hospital Pharmacy 30, 146-152.
30. Shepherd, M. D. and Salzman, R. D. (1994) The formulary decision-making process in a health maintenance organisation setting. PharmacoEconomics 5, 29-38.
31. Soumerai, S. B., McLaughlin, T. J., Ross-Degnan, D., Casteris, C. S. and Bollini, P. (1994) Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331, 650-655.
32. Soumerai, S. B., Ross-Degnan, D., Avorn, J., McLaughlin, T. J. and Choodnovskiy, I. (1991) Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New England Journal of Medicine 325, 1072-1077.
33. Talley, C. R. (1996) Medication formularies in integrated systems. American Journal of Health-System Pharmacy 53, 261.
34. Tanouye, E. (December 7, 1995) Prescription drug prices rose 4.1% in third quarter, exceeding inflation. Wall Street Journal.
35. Weiner, J. P., Lyles, C. A., Steinwachs, D. M. and Hall, K. C. (1991) Impact of managed care on prescription drug use. Health Affairs 10, 140-154.